Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

EGFR wild-type

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	durvalumab + tremelimumab-actl Sensitive: B - Late Trials durvalumab + tremelimumab-actl Sensitive : B	durvalumab + tremelimumab-actl Sensitive: B - Late Trials durvalumab + tremelimumab-actl Sensitive : B
EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	docetaxel + BPI 2358 Sensitive: B - Late Trials docetaxel + BPI 2358 Sensitive : B	docetaxel + BPI 2358 Sensitive: B - Late Trials docetaxel + BPI 2358 Sensitive : B
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	toripalimab-tpzi Sensitive: B - Late Trials toripalimab-tpzi Sensitive : B	toripalimab-tpzi Sensitive: B - Late Trials toripalimab-tpzi Sensitive : B
EGFR wild-type	Lung Non-Small Cell Squamous Cancer	EGFR wild-type	Lung Non-Small Cell Squamous Cancer	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B
EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B
EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: B - Late Trials nivolumab + ipilimumab Sensitive : B	nivolumab + ipilimumab Sensitive: B - Late Trials nivolumab + ipilimumab Sensitive : B
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	docetaxel + BPI 2358 Sensitive: B - Late Trials docetaxel + BPI 2358 Sensitive : B	docetaxel + BPI 2358 Sensitive: B - Late Trials docetaxel + BPI 2358 Sensitive : B
EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	nivolumab + bevacizumab Sensitive: B - Late Trials nivolumab + bevacizumab Sensitive : B	nivolumab + bevacizumab Sensitive: B - Late Trials nivolumab + bevacizumab Sensitive : B
EGFR wild-type	Lung Adenocarcinoma	EGFR wild-type	Lung Adenocarcinoma	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2